Non-Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Assessment of a novel nanoparticle hyperthermia therapy in a murine model of osteosarcoma.


OBJECTIVE: To evaluate the effects of nanoparticle hyperthermia therapy on monocyte function and tumor-derived factors associated with macrophage polarization in a murine osteosarcoma model. STUDY DESIGN: Experimental study. ANIMALS: Female C3H mice. METHODS: Peripheral blood monocyte cell surface phenotype, monocyte chemotaxis, tumor messenger RNA expression, and survival were compared among osteosarcoma (OS)-bearing mice treated with nanoparticle hyperthermia therapy, OS-bearing mice with osteomyelitis, OS-bearing mice, vehicle control mice, and normal control mice. RESULTS: OS-bearing mice with osteomyelitis had a higher proportion of "nonclassical" monocytes (Ly6Clo ) compared with all other experimental groups. There were alterations in monocyte expression of multiple chemokine receptors among experimental groups including CXCR2, CCR2, and CXCR4. Monocytes from OS-bearing mice treated with hyperthermia therapy exhibited greater chemotaxis compared with monocytes from OS-bearing mice with osteomyelitis. CONCLUSION: OS likely induced alterations in monocyte phenotype and function. Nanoparticle hyperthermia therapy increased in vitro monocyte chemotaxis. CLINICAL IMPACT: Enhancing monocyte/macrophage function in dogs with OS may enhance antitumor immunity.

Authors: Tuohy JL, Fogle JE, Meichner K, Borst LB, Petty CS, Griffith EH, Osborne JA, Lascelles BDX
Journal: Vet Surg. 2018 Nov;47(8):1021-1030. doi: 10.1111/vsu.12959. Epub 2018 Oct 11.
Year: 2018
PubMed: PMID: 30307042 (Go to PubMed)